SCHEMBL7926322

SCHEMBL7926322

CCCNS(=O)(=O)c1ccc(OBOc2ccc(S(=O)(=O)NCCC)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.60
CA1 P00915 1/20 0.60
CA2 P00918 1/20 0.60
CA9 Q16790 1/20 0.60
ALDH1A1 P00352 13/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
PKM P14618 1/20 0.54
SMN1; SMN2 Q16637 4/20 0.50
TP53 P04637 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
USP2 O75604 1/20 0.48
TSHR P16473 1/20 0.48
POLB P06746 2/20 0.47
LMNA P02545 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NPC1 O15118 1/20 0.46
MAPT P10636 1/20 0.46
HPGD P15428 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4020471 0.90 ALDH1A1 (0.59) CA12CA1CA2CA9ALDH1A1
SCHEMBL4041550 0.86 ALDH1A1 (0.59) ALDH1A1CYP2C9CYP2C19PKMSMN1; SMN2
SCHEMBL5770948 0.83 ALDH1A1 (0.77) CA12CA1CA2CA9ALDH1A1
SCHEMBL3684870 0.79 CA12 (0.58) CA12CA1CA2CA9ALDH1A1
SCHEMBL11245352 0.78 CA12 (0.81) CA12CA1CA2CA9ALDH1A1
SCHEMBL1962604 0.77 MMP13 (0.45) CA12CA1CA2CA9ALDH1A1
SCHEMBL4050348 0.77 SMN1; SMN2 (0.68) CA12CA1CA2CA9ALDH1A1
SCHEMBL10272435 0.77 CA12 (0.70) CA12CA1CA2CA9ALDH1A1
SCHEMBL634316 0.77 ALDH1A1 (0.71) CA12CA1CA2CA9ALDH1A1
SCHEMBL26214034 0.76 CA12 (0.55) CA12CA1CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6294580-B1 FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE GLAXO WELLCOME INC. 2001-09-25 US disclosed
EP-0888317-B1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LTD (GB) 2001-09-12 EP disclosed
EP-0888317-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1999-01-07 EP disclosed
WO-1997031907-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1997-09-04 WO disclosed